| Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models XY Zhang, MN Trame, LJ Lesko, S Schmidt CPT: pharmacometrics & systems pharmacology 4 (2), 69-79, 2015 | 354 | 2015 |
| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ... The Lancet Oncology 22 (6), 790-800, 2021 | 197 | 2021 |
| Effects of drug–antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody–maytansinoid conjugates X Sun, JF Ponte, NC Yoder, R Laleau, J Coccia, L Lanieri, Q Qiu, R Wu, ... Bioconjugate Chemistry 28 (5), 1371-1381, 2017 | 164 | 2017 |
| Osteonecrosis of the jaw in the United States Food and Drug Administration's adverse event reporting system (FAERS) X Zhang, IS Hamadeh, S Song, J Katz, JS Moreb, TY Langaee, LJ Lesko, ... Journal of Bone and Mineral Research 31 (2), 336-340, 2016 | 95 | 2016 |
| Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors KN Moore, H Borghaei, DM O'Malley, W Jeong, SM Seward, TM Bauer, ... Cancer 123 (16), 3080-3087, 2017 | 77 | 2017 |
| Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues A Husain, X Zhang, MA Doll, DF Barker, DW Hein Drug metabolism and disposition 35 (5), 721-727, 2007 | 72 | 2007 |
| Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1 DF Barker, A Husain, JR Neale, BD Martini, X Zhang, MA Doll, DW Hein Pharmacogenetics and genomics 16 (7), 515-525, 2006 | 64 | 2006 |
| Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements A Husain, X Zhang, MA Doll, DF Barker, DW Hein Drug metabolism and disposition 35 (9), 1649-1656, 2007 | 48 | 2007 |
| A general network pharmacodynamic model–based design pipeline for customized cancer therapy applied to the VEGFR pathway XY Zhang, MR Birtwistle, JM Gallo CPT: pharmacometrics & systems pharmacology 3 (1), 1-9, 2014 | 38 | 2014 |
| Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia N Jain, W Stock, A Zeidan, E Atallah, J McCloskey, L Heffner, B Tomlinson, ... Blood advances 4 (3), 449-457, 2020 | 34 | 2020 |
| 4, 4′-methylenedianiline-induced hepatotoxicity is modified by N-acetyltransferase 2 (NAT2) acetylator polymorphism in the rat X Zhang, JC Lambert, MA Doll, JM Walraven, GE Arteel, DW Hein Journal of Pharmacology and Experimental Therapeutics 316 (1), 289-294, 2006 | 26 | 2006 |
| Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system L Wakefield, V Cornish, H Long, A Kawamura, X Zhang, DW Hein, E Sim Biomarkers 13 (1), 106-118, 2008 | 23 | 2008 |
| High N-Acetyltransferase 1 Expression is Associated with Estrogen Receptor Expression in Breast Tumors, but is not Under Direct Regulation by Estradiol, 5α-androstane-3β, 17β … X Zhang, SM Carlisle, MA Doll, RCG Martin, CM Klinge, DW Hein Journal of Pharmacology and Experimental Therapeutics 365 (1), 84-93, 2018 | 15 | 2018 |
| Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody L Abuqayyas, X Zhang, JP Balthasar International journal of pharmaceutics 444 (1-2), 185-192, 2013 | 14 | 2013 |
| General pharmacokinetic features of small‐molecule compounds exhibiting target‐mediated drug disposition (TMDD): A simulation‐based study T Bach, Y Jiang, X Zhang, G An The Journal of Clinical Pharmacology 59 (3), 394-405, 2019 | 8 | 2019 |
| Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4′-methylene bis (2-chloroaniline) biotransformation DW Hein, X Zhang, MA Doll Toxicology letters 283, 100-105, 2018 | 6 | 2018 |
| Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma B Hess, W Townsend, W Ai, A Stathis, M Solh, JP Alderuccio, D Ungar, ... The AAPS journal 24 (1), 11, 2021 | 2 | 2021 |
| Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL) M Solh, JP Alderuccio, A Stathis, D Ungar, S Liao, L Khouri, X Zhang, ... Cancer Research 81 (13_Supplement), 1366-1366, 2021 | | 2021 |
| Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL) B Hess, W Ai, W Townsend, D Ungar, S Liao, L Liao, X Zhang, J Boni Cancer Research 81 (13_Supplement), 1367-1367, 2021 | | 2021 |
